Paganetti Harald, Simone Charles B, Bosch Walter R, Haas-Kogan Daphne, Kirsch David G, Li Heng, Liang Xiaoying, Liu Wei, Mahajan Anita, Story Michael D, Taylor Paige A, Willers Henning, Xiao Ying, Buchsbaum Jeffrey C
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts; Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts.
New York Proton Center, New York, New York; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):202-217. doi: 10.1016/j.ijrobp.2024.07.2152. Epub 2024 Jul 25.
This position paper, led by the NRG Oncology Particle Therapy Work Group, focuses on the concept of relative biologic effect (RBE) in clinical proton therapy (PT), with the goal of providing recommendations for the next-generation clinical trials with PT on the best practice of investigating and using RBE, which could deviate from the current standard proton RBE value of 1.1 relative to photons. In part 1, current clinical utilization and practice are reviewed, giving the context and history of RBE. Evidence for variation in RBE is presented along with the concept of linear energy transfer (LET). The intertwined nature of tumor radiobiology, normal tissue constraints, and treatment planning with LET and RBE considerations is then reviewed. Part 2 summarizes current and past clinical data and then suggests the next steps to explore and employ tools for improved dynamic models for RBE. In part 3, approaches and methods for the next generation of prospective clinical trials are explored, with the goal of optimizing RBE to be both more reflective of clinical reality and also deployable in trials to allow clinical validation and interpatient comparisons. These concepts provide the foundation for personalized biologic treatments reviewed in part 4. Finally, we conclude with a summary including short- and long-term scientific focus points for clinical PT. The practicalities and capacity to use RBE in treatment planning are reviewed and considered with more biological data in hand. The intermediate step of LET optimization is summarized and proposed as a potential bridge to the ultimate goal of case-specific RBE planning that can be achieved as a hypothesis-generating tool in near-term proton trials.
本立场文件由NRG肿瘤质子治疗工作组牵头,重点关注临床质子治疗(PT)中相对生物效应(RBE)的概念,目的是就PT的下一代临床试验在研究和使用RBE的最佳实践方面提供建议,这可能会偏离目前相对于光子的标准质子RBE值1.1。在第1部分中,回顾了当前的临床应用和实践,介绍了RBE的背景和历史。展示了RBE变化的证据以及线性能量传递(LET)的概念。然后回顾了肿瘤放射生物学、正常组织限制以及考虑LET和RBE的治疗计划之间的相互交织的性质。第2部分总结了当前和过去的临床数据,然后提出了探索和采用工具以改进RBE动态模型的下一步措施。在第3部分中,探讨了下一代前瞻性临床试验的方法,目标是优化RBE,使其既能更真实地反映临床实际情况,又能在试验中应用以实现临床验证和患者间比较。这些概念为第4部分中所综述的个性化生物治疗奠定了基础。最后,我们进行总结,包括临床PT的短期和长期科学重点。结合更多生物学数据,对在治疗计划中使用RBE的实用性和能力进行了回顾和思考。总结了LET优化的中间步骤,并将其作为通向特定病例RBE计划最终目标的潜在桥梁提出,该目标可作为近期质子试验中的假设生成工具来实现。